Reviewing Lantheus (LNTH) & Riot Blockchain (RIOT)

Lantheus (NASDAQ: LNTH) and Riot Blockchain (NASDAQ:RIOT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Valuation & Earnings

This table compares Lantheus and Riot Blockchain’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lantheus $331.38 million 1.51 $123.38 million $1.00 13.10
Riot Blockchain $170,000.00 558.85 -$19.84 million ($2.71) -2.57

Lantheus has higher revenue and earnings than Riot Blockchain. Riot Blockchain is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.


This table compares Lantheus and Riot Blockchain’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lantheus 37.53% 560.19% 9.05%
Riot Blockchain -2,726.37% -125.99% -97.12%

Volatility & Risk

Lantheus has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Comparatively, Riot Blockchain has a beta of 2.49, suggesting that its stock price is 149% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Lantheus and Riot Blockchain, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantheus 0 1 2 0 2.67
Riot Blockchain 0 0 1 0 3.00

Lantheus currently has a consensus price target of $22.67, indicating a potential upside of 73.03%. Riot Blockchain has a consensus price target of $10.00, indicating a potential upside of 43.68%. Given Lantheus’ higher possible upside, research analysts plainly believe Lantheus is more favorable than Riot Blockchain.

Institutional & Insider Ownership

93.1% of Lantheus shares are owned by institutional investors. Comparatively, 12.1% of Riot Blockchain shares are owned by institutional investors. 1.2% of Lantheus shares are owned by insiders. Comparatively, 2.7% of Riot Blockchain shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.


Lantheus beats Riot Blockchain on 10 of the 14 factors compared between the two stocks.

Lantheus Company Profile

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow. The company also offers Neurolite, an injectable that is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures that assess blood flow distribution to the heart. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Riot Blockchain Company Profile

Riot Blockchain, Inc. focuses on building, supporting, and operating blockchain technologies, primarily through its cryptocurrency mining operations and other developed businesses, as well as joint ventures, acquisitions, and targeted investments in the sector. Its primary focus is on Bitcoin and general blockchain technology. The company leverages its expertise and network to build and support blockchain technology companies. It builds a cryptocurrency mining operation and operates specialized computers that generate cryptocurrency, primarily Bitcoin. The company also holds interests in various activities, including purchasing and selling cryptocurrencies; providing accounting, audit, and verification services for blockchain based assets, such as cryptocurrencies; and developing TessPay, a payments ecosystem for component and sub-component supply chain settlements, and other blockchain solutions for telecommunications companies. As of March 31, 2018, approximately 3,500 of the miners were installed and operating. The company was formerly known as Bioptix, Inc. and changed its name to Riot Blockchain, Inc. in October 2017. Riot Blockchain, Inc. was founded in 2000 and is based in Castle Rock, Colorado.

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with's FREE daily email newsletter.

Leave a Reply